Table 1:
Types of CT Tests Offered by Year (N=236)
| 2013 | 2015 | |||||
|---|---|---|---|---|---|---|
| Type of CT Test | In-House N (%) |
Referral N (%) |
Not Offered N (%) |
In-House N (%) |
Referral N (%) |
Not Offered N (%) |
| Culture | 22 (9.3%) | 170 (72.0%) | 44 (18.6%) | 22 (9.3%) | 143 (60.6%) | 69 (29.2%) |
| DFA | 11 (4.7%) | 120 (50.8%) | 105 (44.5%) | 8 (3.4%) | 99 (41.9%) | 127 (53.8%) |
| Hybrid Capture | 3 (1.3%) | 82 (34.7%) | 151 (64.0%) | 2 (0.8%) | 79 (33.5%) | 153 (64.8%) |
| NAAT | 130 (55.1%) | 96 (40.7%) | 9 (3.8%) | 135 (57.2%) | 93 (39.4%) | 7 (3.0%) |
| Rapid test | 8 (3.4%) | 56 (23.7%) | 172 (72.9%) | 6 (2.5%) | 60 (25.4%) | 167 (70.8%) |
| MIF | 2 (0.8%) | 79 (33.5%) | 155 (65.7%) | 2 (0.8%) | 73 (30.9%) | 159 (67.4%) |
| EIA | 2 (0.8%) | 86 (36.4%) | 148 (62.7%) | 7 (3.0%) | 79 (33.5%) | 148 (62.7%) |
| CF | 1 (0.4%) | 78 (33.1%) | 157 (66.5%) | 0 (0.0%) | 78 (33.1%) | 156 (66.1%) |
| Other | 4 (1.7%) | 8 (3.4%) | 224 (94.9%) | 4 (1.7%) | 19 (8.1%) | 213 (90.2%) |
*
DFA = Direct Fluorescent Antibody; NAAT = Nucleic Acid Amplification Testing; MIF = Microimmunofluorescence;
EIA = Enzyme Immunoassay; CF = Complement Fixation